Eve Lalancette, Édith Cantin, Marie-Ève Routhier, Chantal Mailloux, Marie-Claude Bertrand, Dorsa Sadat Kiaei, Valérie Larouche, Uri Tabori, Cynthia Hawkins, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret, Marie-Élaine Métras, Tara McKeown, Luis H Ospina, Stéphanie Vairy, Vijay Ramaswamy, Hallie Coltin, Serge Sultan, Geneviève Legault, Éric Bouffet, Lucie Lafay-Cousin, Juliette Hukin, Craig Erker, Maxime Caru, Mathieu Dehaes, Nada Jabado, Sébastien Perreault, Sarah Lippé
PURPOSE: The use of trametinib in the treatment of pediatric low-grade gliomas (PLGG) and plexiform neurofibroma (PN) is being investigated in an ongoing multicenter phase II trial (NCT03363217). Preliminary data shows potential benefits with significant response in the majority of PLGG and PN and an overall good tolerance. Moreover, possible benefits of MEK inhibitor therapy on cognitive functioning in neurofibromatosis type 1 (NF1) were recently shown which supports the need for further evaluation...
March 5, 2024: Journal of Neuro-oncology